What is LivaNova PLC's (LIVN) StockRank?

MoatMap's StockRank for LivaNova PLC (LIVN) is 83/100, with a Strong Buy signal. This is a composite score combining Quality (62), Value (45), and Momentum (73) factor ranks across MoatMap's universe of 25,000+ stocks.

Does LivaNova PLC have an economic moat?

LivaNova PLC (LIVN) has a Quality factor score of 62/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is LivaNova PLC a buy, hold, or sell?

MoatMap's current signal for LivaNova PLC (LIVN) is Strong Buy, based on a StockRank of 83/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is LivaNova PLC in?

LivaNova PLC (LIVN) operates in the Healthcare sector, specifically the Medical Devices industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

LIVN

Strong BuyPremium Grower

LivaNova PLC · Healthcare · United Kingdom · $4.4B · Avg Vol: $53M/d

StockRank

Get insider-trade alerts

P/E (TTM)

24.2x

ROE

15.4%

D/E

0.3x

Dividend %

—

COMPANY DESCRIPTION

LivaNova PLC is a global medical technology company dedicated to developing innovative solutions for cardiovascular and neuromodulation therapies, including heart-lung machines and vagus nerve stimulation (VNS) for epilepsy and depression. The company maintains a competitive moat through its proprietary technologies, extensive R&D, and strong intellectual property in highly specialized and regulated medical device markets.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	1.0B	1.2B	1.3B	1.4B	10.8%	1.5B	1.5B	1.6B	8.4%
EPS	-1.61	0.33	1.17	-4.45	254.5%	3.39	4.36	4.68	58.7%
Shares	53.6M	53.9M	54.3M	54.6M	+2.0%	54.9M	—	—	—
Debt	580.4M	640.4M	676.8M	433.8M	-9.3%	351.9M	—	—	—
Equity	1.2B	1.3B	1.3B	1.2B	-0.2%	—	—	—	—
Op CF	69.9M	74.9M	183.0M	254.3M	53.8%	249.3M	—	—	—
Inv CF	-38.4M	-40.3M	-48.2M	-72.9M	—	—	—	—	—
Fin CF	280.1M	21.5M	18.6M	-285.7M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)-3.1%

SMA 50SMA 200

$78.93

RSI (14)

43.0

52W High

$85.76

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

8.0%64.9

ROE

15.4%82.5

GP/Assets

38.3%75.8

Op. Margin

13.5%71.6

FCF/Assets

5.7%72.6

Piotroski

431.0

Int. Cover

3.9x48.3

D/E Ratio

0.27x44.2

Current Ratio

1.45x25.2

Value

P/E (TTM)

24.2x50.7

EV/EBITDA

16.6x43.6

P/FCF

29.8x46.0

P/B

3.4x41.4

P/S

3.1x56.0

Div Yield

—N/A

Momentum

52W High %

92%89.1

RS 6M

14%77.5

SMA 50/200

1.15x83.2

EPS Rev 4W

+0.9%47.9

EPS Rev 12W

+1.0%51.1

EPS Improve

+38%47.1

Q Growth

300%94.6

FUNDAMENTALS

Market Cap

$4.4B

P/E (Forward)

17.5x

Gross Margin

67.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LIVN are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
LIVN	LivaNova PLC(you)	$4.4B	83	Strong Buy
SN.L	Smith & Nephew plc	$12.0B	79	Buy
NIOX.L	NIOX Group Plc	$387M	83	Strong Buy
EKF.L	EKF Diagnostics Holdings plc	$147M	83	Strong Buy
KNSA	Kiniksa Pharmaceuticals International, plc	$6.1B	79	Buy
HIK.L	Hikma Pharmaceuticals PLC	$4.5B	94	Strong Buy
CTEC.L	Convatec Group PLC	$6.0B	73	Buy
SPI.L	Spire Healthcare Group plc	$1.3B	88	Strong Buy
AMS.L	Advanced Medical Solutions Group plc	$831M	84	Strong Buy
GNS.L	Genus plc	$2.1B	62	Hold

Peer medians: ROE -4.1% · P/E 25.0x · Gross margin 55.3%